0001558370-23-015209.txt : 20230823 0001558370-23-015209.hdr.sgml : 20230823 20230823125714 ACCESSION NUMBER: 0001558370-23-015209 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230822 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230823 DATE AS OF CHANGE: 20230823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nutex Health, Inc. CENTRAL INDEX KEY: 0001479681 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 113363609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41346 FILM NUMBER: 231196430 BUSINESS ADDRESS: STREET 1: 6030 S. RICE AVE. STREET 2: SUITE C CITY: HOUSTON STATE: TX ZIP: 77081 BUSINESS PHONE: (713) 660-0557 MAIL ADDRESS: STREET 1: 6030 S. RICE AVE. STREET 2: SUITE C CITY: HOUSTON STATE: TX ZIP: 77081 FORMER COMPANY: FORMER CONFORMED NAME: Clinigence Holdings, Inc. DATE OF NAME CHANGE: 20191113 FORMER COMPANY: FORMER CONFORMED NAME: iGambit, Inc. DATE OF NAME CHANGE: 20091230 8-K 1 nutx-20230822x8k.htm 8-K
0001479681false00014796812023-08-222023-08-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 22, 2023

 

NUTEX HEALTH INC.

(Exact name of registrant as specified in its charter)

 

Delaware

001-41346

11-3363609

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(I.R.S. Employer
Identification Number)

6030 S. Rice AveSuite CHoustonTexas 77081

(Address of principal executive offices) (zip code)

 

‎(713660-0557

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

 NUTX

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

On August 22, 2023, Nutex Health Inc. (“Nutex” or the “Company”) issued a press release relating to its acquisition of all the issued and outstanding shares of stock of Population Health Associates, Inc. (“PHA”) and Managed Care Insurance Consultants, Inc. (“MCIC”). A copy of that press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 

Exhibit No.

Description of Exhibit

99.1

Press Release dated August 22,2023

104

Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

THE INFORMATION CONTAINED IN ITEM 8.01 OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED "FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 23, 2023

Nutex Health Inc.

By: /s/ JON C. BATES

Jon C. Bates

Chief Financial Officer

EX-99.1 2 nutx-20230822xex99d1.htm EX-99.1

Exhibit 99.1

Graphic

NUTEX HEALTH ANNOUNCES THE ACQUISITION OF POPULATION HEALTH ASSOCIATES
AND MANAGED CARE INSURANCE CONSULTANTS

ACQUISITION EXPANDS COMPANY’S PRESENCE IN FLORIDA AND ADDS APPROXIMATELY 112 PRIMARY CARE
PHYSICIANS AND 4400 MANAGED CARE PATIENTS TO THE NUTEX PLATFORM

HOUSTON, TX − (PRNewswire) – August 22, 2023 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced that it has acquired Population Health Associates, Inc. (“PHA”) and Managed Care Insurance Consultants, Inc. (“MCIC”).

Founded in 1996 and based in Coral Gables, Florida, PHA and MCIC are independent practice associations (“IPAs”) that provide high-quality, coordinated care to approximately 4400 managed care patients through a network of approximately 112 primary care physicians (“PCPs”) in South, Central and North Florida.  As part of the acquisition, Victor Behar, Founder and CEO of PHA and MCIC, will lead all Florida IPA operations for Nutex Health.

The acquisition of PHA and MCIC will add approximately 4400 managed care patients to Nutex Health’s existing 25,000 managed care patients, creates synergies with South Florida Physicians IPA (“SFPIPA”), Nutex’s existing network of PCPs in South Florida and leverages Nutex’s proprietary cloud-based population health management technology platform, called Clinigence Health.  The Company expects to optimize medical cost ratios (“MCRs”) and to deliver improved health outcomes for its patients.

“Nutex expects to open 5-6 Florida micro-hospitals in Tampa, Miami, Orlando and Jacksonville by the end of 2025. We believe that our integrated healthcare delivery model of micro-hospitals surrounded by our own affiliated network of physicians, once operational, should translate into higher patient volumes for our hospitals while lowering the MCRs for our IPAs, making both the micro-hospitals and IPAs more profitable,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

“We welcome Mr. Behar and his team to the Nutex family and are excited to partner with the PHA and MCIC physicians in providing high-quality value-based care to our patients.  This acquisition accelerates our expansion in Florida and represents the continued execution of our growth strategy of building or buying IPAs around our facilities”, stated Warren Hosseinion, M.D., President of Nutex Health.

“We are thrilled to become part of Nutex Health and believe that our network of providers will benefit from the support and cloud-based population health management platform provided by Clinigence,” stated Victor Behar, Chief Executive Officer of PHA and MCIC.

Page 1 of 2


About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 22 facilities in 8 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.  Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company.  Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-Q for the period ended June 30, 2023 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

FOR ADDITIONAL INFORMATION:

Nutex Health, Inc.

Jennifer Smith Rodriguez

Investor Relations & Media Contact

jsmith@nutexhealth.com

Page 2 of 2


GRAPHIC 3 nutx-20230822xex99d1001.jpg GRAPHIC begin 644 nutx-20230822xex99d1001.jpg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end EX-101.SCH 4 nutx-20230822.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 nutx-20230822_def.xml EX-101.DEF EX-101.LAB 6 nutx-20230822_lab.xml EX-101.LAB EX-101.PRE 7 nutx-20230822_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 22, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Aug. 22, 2023
Entity Registrant Name NUTEX HEALTH INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-41346
Entity Tax Identification Number 11-3363609
Entity Address, Address Line One 6030 S. Rice Ave
Entity Address, Adress Line Two Suite C
Entity Address, City or Town Houston
Entity Address State Or Province TX
Entity Address, Postal Zip Code 77081
City Area Code 713
Local Phone Number 660-0557
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol NUTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001479681
Amendment Flag false
XML 9 nutx-20230822x8k_htm.xml IDEA: XBRL DOCUMENT 0001479681 2023-08-22 2023-08-22 0001479681 false 8-K 2023-08-22 NUTEX HEALTH INC. DE 001-41346 11-3363609 6030 S. Rice Ave Suite C Houston TX 77081 713 660-0557 false false false false Common Stock, $0.001 par value NUTX NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://nutexhealth.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports nutx-20230822x8k.htm nutx-20230822.xsd nutx-20230822_def.xml nutx-20230822_lab.xml nutx-20230822_pre.xml nutx-20230822xex99d1.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nutx-20230822x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "nutx-20230822_def.xml" ] }, "inline": { "local": [ "nutx-20230822x8k.htm" ] }, "labelLink": { "local": [ "nutx-20230822_lab.xml" ] }, "presentationLink": { "local": [ "nutx-20230822_pre.xml" ] }, "schema": { "local": [ "nutx-20230822.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nutx", "nsuri": "http://nutexhealth.com/20230822", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "nutx-20230822x8k.htm", "contextRef": "Duration_8_22_2023_To_8_22_2023_odrxZSNGQkCrRezWj-_L1A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "nutx-20230822x8k.htm", "contextRef": "Duration_8_22_2023_To_8_22_2023_odrxZSNGQkCrRezWj-_L1A", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://nutexhealth.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001558370-23-015209-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-015209-xbrl.zip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end